[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Unidade Local de Saúde do Alto Ave, EPE\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":85},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100653641","sleep-and-arterial-function-in-hypertensive-patients-with-poor-sleep-quality-100653641",false,"NCT07789535","Sleep and Arterial Function in Hypertensive Patients With Poor Sleep Quality","Impact of Sleep on Arterial Function, Psychological and Cognitive Complaints in Hypertensive Patients With Poor Sleep Quality","SLEEP-ARTerY","Inclusion Criteria:\n\n* Adults aged 18 to 70 years\n* Controlled hypertension\n* Poor baseline sleep quality (sleep efficiency \\\u003C=85% assessed via actigraphy or type II polysomnography)\n* Capable of providing informed consent\n* Participants with mild obstructive sleep apnea (apnea-hypopnea index 5-14.9\u002Fh on type II polysomnography) who do not meet criteria for CPAP\u002FPAP therapy are eligible\n\nExclusion Criteria:\n\n* Severe cardiovascular disease (e.g., acute myocardial infarction or stroke)\n* Severe neurological diseases\n* Moderate-to-severe obstructive sleep apnea (AHI \\>=15\u002Fh) or any obstructive sleep apnea with an indication for CPAP\u002FPAP therapy\n* Central disorders of hypersomnolence\n* Intellectual disability\n* Pregnancy","ALL","18 Years","70 Years",{"count":21,"type":22},234,"ESTIMATED","INTERVENTIONAL",[25],"NA","This prospective, parallel-group randomised controlled trial evaluates whether cognitive-behavioural therapy for insomnia (CBT-I) improves arterial function and psychological and cognitive outcomes in hypertensive patients with poor sleep quality. Adults aged 18-70 with controlled hypertension and poor baseline sleep quality (sleep efficiency \\\u003C=85%) are randomised 1:1 to CBT-I (four weekly 60-minute sessions) or passive sleep education. The primary outcomes are change from baseline in pulse wave velocity and central arterial pressure at 12 months. Secondary outcomes include blood pressure, depressive symptoms, perceived stress, cognitive complaints, and sleep quality, assessed at baseline, 1, 6, and 12 months.",[28,29,30,31],"Hypertension","Poor Sleep Quality","Insomnia","Arterial Stiffness",[33,34,35,36,37,38,39,40],"sleep quality","arterial stiffness","CBT-I","pulse wave velocity","central arterial pressure","hypertension","depression","cognitive function","RECRUITING","2026-08-24",{"date":44,"type":45},"2026-08-27","ACTUAL",{"date":47,"type":45},"2026-05-18",{"date":49,"type":22},"2030-03",{"name":51,"class":52},"Unidade Local de Saúde do Alto Ave, EPE","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":53},"100623408","phase-2-comparison-between-transarterial-musculoskeletal-embolization-and-platelet-rich-plasma-injection-for-the-treatment-of-greater-trochanteric-pain-syndrome-100623408","NCT07396246","Comparison Between Transarterial Musculoskeletal Embolization and Platelet-Rich Plasma Injection for the Treatment of Greater Trochanteric Pain Syndrome","The HIPE RCT - Comparison Between Transarterial Musculoskeletal Embolization (TAME) and Platelet-Rich Plasma (PRP) Injection for the Treatment of Greater Trochanteric Pain Syndrome - A Randomized Controlled Trial","HIPE","Inclusion Criteria:\n\n* Diagnosis of GTPS confirmed by clinical and imaging assessments\n* Persistent symptoms despite at least 3 months of conservative treatment (e.g., physical therapy, NSAIDs)\n* Willingness to participate and provide informed consent\n* Availability for follow-up assessments at 1, 3, 6, and 12 months post-treatment\n\nExclusion Criteria:\n\n* Prior hip surgery or other interventions (e.g., joint replacement, prior PRP injections or embolization)\n* Severe osteoarthritis (Tonnis III)\n* Active lumbar radiculopathy with pain, numbness, or weakness in a dermatomal distribution\n* Contraindications for PRP injections (e.g., active infection, coagulopathy, antiplatelet or anticoagulation therapy,\n* Pregnancy or breastfeeding\n* Severe comorbidities that would interfere with participation\n* Active cancer or other malignancies","80 Years",{"count":64,"type":22},30,[66],"PHASE2","Greater Trochanteric Pain Syndrome (GTPS) is a common cause of lateral hip pain that can significantly affect daily activities and quality of life. Standard treatments include physical therapy, anti-inflammatory medications, and local injections, but many patients continue to experience persistent symptoms.\n\nThis randomized controlled trial aims to compare two minimally invasive treatment options for GTPS: transarterial musculoskeletal embolization (TAME) and platelet-rich plasma (PRP) injection. Participants will be randomly assigned to receive either TAME or PRP.\n\nThe main goal of the study is to evaluate which treatment is more effective in reducing pain. Secondary goals include comparing functional improvement, quality of life, and safety between the two treatments. Pain and functional outcomes will be assessed at baseline and during follow-up at 1, 3, 6, and 12 months after treatment.\n\nThis study seeks to provide evidence on the effectiveness and safety of TAME compared with PRP injection for patients with Greater Trochanteric Pain Syndrome.",[69],"Trochanteric Syndrome",[71,72,73,74,75,76],"Embolization","Musculoskeletal","Hip","Greater Trochanter Pain Syndrome","Pain management","PRP","2026-02-01",{"date":79,"type":45},"2026-02-09",{"date":81,"type":45},"2026-01-05",{"date":83,"type":22},"2027-12-31",{"name":51,"class":52},""]